Revenue Breakdown
Composition ()
No data
Revenue Streams
Beta Bionics Inc (BBNX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DME channel - iLet, accounting for 52.0% of total sales, equivalent to $14.18M. Other significant revenue streams include DME channel - Single-use products and PBP channel - Single-use products. Understanding this composition is critical for investors evaluating how BBNX navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Beta Bionics Inc maintains a gross margin of 55.48%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -62.54%, while the net margin is -52.14%. These profitability ratios, combined with a Return on Equity (ROE) of -236.20%, provide a clear picture of how effectively BBNX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BBNX competes directly with industry leaders such as AVNS and DRTS. With a market capitalization of $574.96M, it holds a significant position in the sector. When comparing efficiency, BBNX's gross margin of 55.48% stands against AVNS's 48.37% and DRTS's N/A. Such benchmarking helps identify whether Beta Bionics Inc is trading at a premium or discount relative to its financial performance.
